ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2747

Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide

Mert Gurcan1, Sinem Nihal Esatoglu1, Vedat Hamuryudan1, Caner Saygin2, Didem Saygin3, Serdal Ugurlu4, Emire Seyahi1, Melike Melikoglu1, Izzet Fresko1, Sebahattin Yurdakul1, Hasan Yazici1 and Gulen Hatemi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Cleveland, OH, 3Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, 4Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Behcet's syndrome, cyclophosphamide and outcomes

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Session Title: Vasculitis Poster III: Other Vasculitis Syndromes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

 

Background/Purpose: Cyclophosphamide (CYC) remains an important treatment option for Behçet’s syndrome (BS) pts with life threatening conditions such as arterial aneurysms. However, several adverse events are associated with CYC treatment and this has led to increased use of biologic agents such as rituximab in other vasculitides. The aim of this study is to survey the outcome and short and long term adverse events with CYC use among BS pts.

Methods: We conducted a retrospective chart review of all BS patients treated with oral or intravenous CYC between 1972 and 2006.  Patients were called and a standard form was used for collecting demographic characteristics, indication for CYC use, the reason for the cessation of therapy, cumulative dose of CYC, short and long term adverse events and outcome.

Results: We evaluated 99 pts who had an available contact information. After a median follow up of 18 (12-26) yrs after the initiation of CYC therapy, 27 pts had died within a median follow-up of 4 (0-10) yrs, 13 were lost after a median follow-up of 2.5 (0-11) yrs, and 59 were reached. CYC was prescribed for vascular involvement in 62 pts, eye involvement in 24, central nervous system involvement in 2, both vascular and eye involvement in 8 and both vascular and central nervous system involvement in 2. The median duration of CYC use and cumulative dose of CYC were 16 (6-63) gr and 12 (3-26) mo respectively. The reasons for death among the pts were shown in Table.

Twelve pts experienced serious adverse events associated with short term CYC use and 1 of them died due to infection. Among these adverse events, hemorrhagic cystitis occurred in 3 pts, infections in 5, ischemic stroke, acute myocardial infarction, anaphylactic reaction and grand mal epileptic seizure in 1 patient each. CYC treatment was terminated due to refractory disease in 30 pts and adverse events in 13. CYC induction was completed with beneficial results in the remaining 56 pts. During long term follow-up, malignancies and/or cardiovascular disease occurred in 27% of the pts. Overall, 9 malignancies were observed in 8 pts after a median follow up of 20 (12-25) yrs. The malignancies were t-MDS-AML, bladder carcinoma (n=2), lymphoma (n=2), HCC, colon adenocarcinoma, squamous cell carcinoma and prostate adenocarcinoma. Sixteen pts had cardiovascular disease and 3 had stroke.

Conclusion: CYC treatment was effective in about half of the pts. Serious adverse events including infections and malignancies occurred in 12% of the pts during CYC treatment and malignancies and cardiovascular events in 27% of the pts during long term follow-up. Other immunosuppressives used by these pts may also have contributed to these results and concomitant use of high dose corticosteroids may be responsible for the cardiovascular events. These results underline the need for safer and effective alternatives to CYC for serious organ involvement in BS, similar to that in other vasculitides.

 

 

Table. The reasons for death in 27 of the surveyed 99 BS patients treated with cyclophosphamide

Cause of death

n

Vascular involvement

12

     Pulmonary artery aneurysm

7

                  Abdominal aorta aneurysm

2

                  Budd-Chiari syndrome

3

Malignancy

3

                   t-MDS/AML

1

                   Hepatocellular carcinoma

1

                   SVCT due to high grade lymphoma

1

Infection

4

                 Pneumonia

3

                  Tuberculosis

1

Ischemic stroke

1

Traffic accident

1

Unknown

6

SVCT:  superior vena cava thrombosis; t-MDS/AML: therapy related myelodysplastic syndrome-acute myeloid leukemia

 

 


Disclosure: M. Gurcan, None; S. N. Esatoglu, None; V. Hamuryudan, None; C. Saygin, None; D. Saygin, None; S. Ugurlu, None; E. Seyahi, None; M. Melikoglu, None; I. Fresko, None; S. Yurdakul, None; H. Yazici, None; G. Hatemi, None.

To cite this abstract in AMA style:

Gurcan M, Esatoglu SN, Hamuryudan V, Saygin C, Saygin D, Ugurlu S, Seyahi E, Melikoglu M, Fresko I, Yurdakul S, Yazici H, Hatemi G. Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/long-term-follow-up-of-behcets-syndrome-patients-treated-with-cyclophosphamide/. Accessed May 19, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-follow-up-of-behcets-syndrome-patients-treated-with-cyclophosphamide/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.